Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
(Date:8/19/2014)... One of the major limitations ... inadequate vascular supply. Nutrient and gas transport throughout ... critical for successful regeneration and integration into the ... in vascularization and promote angiogenesis in a variety ... design and architecture, and enhancing scaffolds with stem ...
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... InterWest Partners,announced today the appointment of ... firm,s Advisory Committee: Caltech,president Dr. Jean-Lou Chameau, ... commissioner Dr. Mark McClellan. The three will ... strategic guidance,to the firm and its portfolio ...
... S. Young awarded "Most Innovative" award by the Association of ... ... Research Inc. (TSX:,ARI), a biotechnology company discovering and developing the ... Young, President,and Chief Executive Officer, received the "Most Innovative" award ...
... to dramatically reduce their dose of these often harsh ... Medicine in St. Louis have taken a step closer ... drug directly on tumors in rabbits using drug-coated nanoparticles. ... than used previously for this purpose markedly slowed tumor ...
Cached Biology Technology:Prestigious Scientific Leaders Join InterWest Advisory Committee 2Prestigious Scientific Leaders Join InterWest Advisory Committee 3Prestigious Scientific Leaders Join InterWest Advisory Committee 4ARIUS recognized for entrepreneurial excellence 2Nanosized technology has supersized effect on tumors 2Nanosized technology has supersized effect on tumors 3
(Date:8/20/2014)... During the past few years, Virginia Tech,s Wu Feng ... Microsoft grant from the "Computing in the Cloud" program, ... a $6 million award from the Air Force on ... from NSF and the National Institutes of Health on ... wove together the "parallel computing" aspects from each grant, ...
(Date:8/20/2014)... of honeybees grows to about 4,000 members, it triggers ... building of a special type of comb used for ... from the Department of Neurobiology and Behaviour at Cornell ... reproductive cycle of honeybee colonies. The results are published ... Nature . , Reproduction isn,t always a honeybee ...
(Date:8/20/2014)... 2014  The second annual Biometrics UnPlugged Executive ... Tampa, Florida on September 15, 2014, ... Technology and Strategy at Samsung, and Philippe de ... of this year,s event is Mobility at the ... "Biometrics UnPlugged: Mobility at the Crossroads of Commerce ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... an inherited structural mechanism that can make drugs ... mechanism decreases a protein and in turn causes ... therapies are used to treat patients with childhood ... researchers say their finding advances the field of ...
... may account for many cases of immune deficiency, in ... and Common Variable Immunodeficiency (CVID), report researchers in the ... to a new diagnostic test for these conditions, which ... unrecognized because of a lack of good tests. , ...
... Broken sewers, flooded industrial plants and dead bodies are all likely ... , But the water - and the muck it is leaving ... as it is unexpected: Toxins common in most urban environments that ... atop the city. , So says a University of Florida professor ...
Cached Biology News:Genomics researchers discover protein deficit that causes drug toxicity 2Protein amplification in melanoma is possible drug target 2Toxic flood lifts lid on common urban pollution problem 2Toxic flood lifts lid on common urban pollution problem 3
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: ... region encompassing the human, mouse, ... Accession Number: ... Assurance: Routinely evaluated by ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: